...
首页> 外文期刊>Journal of chemotherapy >Susceptibility to antibiotics of aerobic bacteria isolated from community acquired secondary peritonitis in children: Therapeutic guidelines might not always fit with and everyday experience
【24h】

Susceptibility to antibiotics of aerobic bacteria isolated from community acquired secondary peritonitis in children: Therapeutic guidelines might not always fit with and everyday experience

机译:从社区获得性继发性腹膜炎中分离出的需氧细菌对抗生素的敏感性:治疗指南可能并不总是适合日常使用

获取原文
获取原文并翻译 | 示例
           

摘要

Appendicitis is a frequent clinical condition in normal children that may be complicated by community-acquired secondary peritonitis (CASP). We evaluated the potential efficacy of different drugs for initial treatment of this condition, as recommended by recent Consensus Conference and Guidelines for paediatric patients. Susceptibility to ampicillin-sulbactam, ertapenem, gentamycin, piperacillin, piper-acillin-tazobactam, vancomycin, and teicoplanin was evaluated according to EUCST 2012 recommenda-tions in aerobic bacteria isolated from peritoneal fluid in CASP diagnosed from 2005 to 2011 at 'Istituto Giannina Gaslini', Genoa, Italy. A total of 114 strains were analysed: 83 E. coli, 15 P. aeruginosa, 6 Enterococci, and 10 other Gram-negatives. Resistance to ampicillin-sulbactam was detected in 37% of strains, while ertapenem showed a potential resistance of 13% (all P. aeruginosa strains). However, the combination of these drugs with gentamicin would have been increased the efficacy of the treatment to 99 and 100%, respectively. Resistance to piperacillin-tazobactam was 3%, while no strain was resistant to meropenem. Our data suggest that monotherapy with ampicillin-sulbactam or ertapenem for community-acquired secondary peritonitis would present a non-negligible rate of failure, but the addition of gentamycin to these drugs could reset to zero this risk. On the contrary, monotherapy with piperacillin-tazobactam or meropenem is highly effective.
机译:阑尾炎是正常儿童的常见临床症状,可能会因社区获得性继发性腹膜炎(CASP)而并发。根据最近的共识会议和《儿科患者指南》的建议,我们评估了不同药物对该病的初始治疗的潜在疗效。根据EUCST 2012建议对从CASP腹膜液中分离出的需氧细菌进行2005年至2011年间诊断为加尼西尼亚(Istituto Giannina)的有氧细菌对氨苄西林-舒巴坦,厄他培南,庆大霉素,哌拉西林,哌拉西林-他唑巴坦,万古霉素和替考拉宁的敏感性',意大利热那亚。共分析了114株菌株:83株大肠杆菌,15株铜绿假单胞菌,6株肠球菌和10株其他革兰氏阴性菌。在37%的菌株中检测到对氨苄西林舒巴坦的耐药性,而ertapenem的潜在耐药性为13%(所有铜绿假单胞菌菌株)。但是,这些药物与庆大霉素的组合将使治疗的效力分别提高到99%和100%。对哌拉西林-他唑巴坦的耐药率为3%,而没有菌株对美罗培南耐药。我们的数据表明,氨苄西林-舒巴坦或厄他培南单一疗法治疗社区获得性继发性腹膜炎的失败率不可忽略,但是向这些药物中添加庆大霉素可使该风险降至零。相反,使用哌拉西林-他唑巴坦或美罗培南的单一疗法非常有效。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号